English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Address: 1Department of Obstetrics and Gynecology, University Hospital, Essen, Germany, 2Department of Obstetrics and Gynecology, University Hospital Munich/Grosshadern, Munich, Germany, 3Research Center for Oncology, Moscow, Russia, 4Department of Obstetrics and Gynecology, University Hospital Munich-City, Munich, Germany, 5Department of Gynecology, University Hospital Technical University, Munich, Germany, 6Department of Obstetrics and Gynecology, University Hospital, Kiel, Germany, 7Moscow Oncology Clinical Hospital, Moscow, Russia, 8Department of Surgery, University Hospital Munich/Grosshadern, Munich, Germany, 9Frauenklinik vom Roten Kreuz, Munich, Germany, 10Central Clinical Hospital of Ministry, Moscow, Russia, 11St. Petersburg Scientific Oncology Institute, St. Petersburg, Russia and 12Department of Gynecology and gynecological Oncology, Dr. Horst-Schmidt-Kliniken, Wiesbaden, Germany

cancer cell international

Tolerability and efficacy of the trifunctional antibody removab<sup>® </sup>(anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study

Tolerability and efficacy of the trifunctional antibody removab® (anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study

Tolerability and efficacy of the trifunctional antibody removab^®(anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study